Radiographic response
Taltz helped stop the progression of structural joint damage at week 16 vs placebo1-3,7
Primary endpoint=ACR20 response at week 24.
Inhibition of progression of structural damage was assessed radiographically and expressed as the mean change in mTSS and its components, the joint space narrowing score and bone erosion score, at week 16 vs baseline. The mTSS score was modified for psoriatic arthritis by addition of hand distal interphalangeal (DIP) joints.
SPIRIT-P2 (TNFi-experienced) did not include an assessment of radiographic progression.
mTSS=modified Total Sharp Score; MMRM=mixed-effect model of repeated measure.
SELECT IMPORTANT SAFETY INFORMATION
INFLAMMATORY BOWEL DISEASE
Patients treated with Taltz may be at an increased risk of inflammatory bowel disease. In clinical trials, Crohn’s disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the Taltz group than the placebo group. During Taltz treatment, monitor patients for onset or exacerbation of inflammatory bowel disease and if IBD occurs, discontinue Taltz and initiate appropriate medical management.
89% of Taltz patients had almost no progression of structural joint damage* at week 528,9
Mean change from baseline in mTSS at week 52 was 0.47 for patients in the extension period on Taltz 80 mg every 4 weeks.
SELECT IMPORTANT SAFETY INFORMATION
IMMUNIZATIONS
Prior to initiating Taltz, consider completion of all ageappropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with Taltz.